StocksFin Logo
BeiGene, Ltd. country of incorporation
|
|
Mr. John V. Oyler
|
9,000 employees
NASDAQ | Healthcare | Biotechnology
Alnylam Pharmaceuticals, Inc. country of incorporation
|
|
Dr. John Maraganore
|
1,665 employees
NASDAQ | Healthcare | Biotechnology
Q322 reported Nov 9, 2022 Reporting Period
$387.63M 87.8% vs. Q321 Revenues Q322
-29.74% 68.2% vs. Q321 Gross Profit Margin
-143.84% ! 28.3% vs. Q321 Net Profit Margin
-690.56M ! -39.3% vs. Q321 Free Cash Flow Q322
$-5.33 ! -20.6% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Q322 reported Oct 27, 2022 Reporting Period
$264.31M 40.9% vs. Q321 Revenues Q322
84.44% 2.2% vs. Q321 Gross Profit Margin
-153.58% ! -40.9% vs. Q321 Net Profit Margin
-131.79M ! 1.7% vs. Q321 Free Cash Flow Q322
$-3.32 ! -93% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Loading...
Loading...
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
3.74
3.17
Current Ratio
4.07
3.48
Cash Ratio
2.97
1.39
Price to Book
3
-361.52
Price to Sales
35.99
92.52
Price to Earnings
-6.26
-15.06